Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

Nasser MikhailEndocrinology Division, Olive View-UCLA Medical Center, David-Geffen School of Medicine, CA, USAAbstract: Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the en...

Full description

Bibliographic Details
Main Author: Nasser Mikhail
Format: Article
Language:English
Published: Dove Medical Press 2008-12-01
Series:Vascular Health and Risk Management
Subjects:
Incretins
sitagliptin
vildagliptin
dipeptidyl peptidase inhibitors
pioglitazone
type 2 diabetes
Online Access:https://www.dovepress.com/combination-therapy-with-dpp-4-inhibitors-and-pioglitazone-in-type-2-d-peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/combination-therapy-with-dpp-4-inhibitors-and-pioglitazone-in-type-2-d-peer-reviewed-article-VHRM

Similar Items